Stay updated with breaking news from Abderrahim Oukessou. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with KRAZATI compared to standard of care...
The positive results in both progression-free survival and overall response rate were endorsed in a confirmatory study.
Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 28, 2024--
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally...